Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: J Immunol. 2015 May 13;194(12):5937–5947. doi: 10.4049/jimmunol.1500089

Figure 1. XBP1 plays a decisive role in improving therapeutic DC vaccine potency.

Figure 1

a–c) XBP1 improves therapeutic DC vaccine efficacy. DC were untreated or transfected with XBP1/NeuEDhsp70, XBP1/TRP2hsp70 or control DNA. BALB/c or B6 mice were inoculated with 4T1.2-Neu (a–b) or GL26 (c) on day 0. On day 8, tumor-bearing mice were randomized into cohorts and left untreated or they were vaccinated once with the indicated DC populations.

d) Inhibition of XBP1 activity reduces XBP1-potentiated therapeutic DC vaccine efficacy. DC were transfected with XBP1/NeuEDhsp70 in the absence or presence of dnXBP1 or control (Ctl) vector. Therapeutic vaccination in 4T1.2-Neu-bearing mice was then performed as in (a).

Tumor growth was then monitored, reported and statistically-analyzed as outlined in Materials and Methods. Data from two independent experiments are shown.